UK: Oral COVID-19 antiviral, Paxlovid, approved by MHRA
The UK's Medicines and Healthcare Products Regulator Agency (MHRA) announced on Friday that they have approved the oral COVID-19 antiviral, Paxlovid, as reported by Reuters.
Key takeaways
"New combination treatment is for people with mild to moderate COVID-19 who are at high risk of developing severe COVID-19."
"Too early to know whether Omicron variant has any impact on Paxlovid's effectiveness."
"Number of hospitalisations and deaths were 0.8% (3 out of 389) in the Paxlovid group compared with 7% (27 out of 385) in the placebo group."
"The two active substances of Paxlovid come as separate tablets that are packaged together and taken together, twice a day by mouth for 5 days."
"MHRA is proactively working with the company to establish the effectiveness of Paxlovid against omicron."
"Paxlovid authorised for use in people aged 18 & above who have mild to moderate COVID-19 infection & at least 1 risk factor for developing severe illness."
"Based on clinical trial data, Paxlovid is most effective when taken during the early stages of infection."
"Before Paxlovid is prescribed, MHRA is advising that patients' current medications should be carefully reviewed."
Market reaction
This headline doesn't seem to be having a noticeable impact on risk sentiment.
Reprinted from FXStreet_id,the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.